Washington, D.C. - The U.S. Patent and Trademark Office ("USPTO") recently announced the release of the Patent Application Alert Service. This system provides customized email alerts to the public for free when patent applications of interest are published. Additionally, the system offers direct access to the published applications that meet users' search criteria.
After receipt of these customized email alerts, the public may identify prior art for "pre-issuance" submission into these applications. The pre-issuance submission process was established under the America Invents Act and, to date, the Office has received more than 2,600 submissions across all technologies. More information on the pre-issuance submission program and how members of the public can participate can be found here.
The idea for the patent application alert service came from a public roundtable held at the USPTO in April 2014 where the USPTO solicited input regarding the use of crowdsourcing and pre-issuance submissions to identify relevant prior art. The USPTO expects that this new service may be used to enhance the quality of examination and issued patents.
Recently in Patent Application Prosecution Category
Washington, D.C. - The U.S. Patent and Trademark Office ("USPTO") recently announced the release of the Patent Application Alert Service. This system provides customized email alerts to the public for free when patent applications of interest are published. Additionally, the system offers direct access to the published applications that meet users' search criteria.
What can be patented?
Utility patents are available for a new, nonobvious and useful:
• Article of manufacture,
• Composition of matter, or
• Improvement of any of the above
Patent protection is also available for (1) ornamental design of an article of manufacture or (2) asexually reproduced plant varieties.
What cannot be patented:
• Laws of nature,
• Physical phenomena,
• Abstract ideas,
• Literary, dramatic, musical, and artistic works (these may be protected under copyright law), or
• Inventions which are 1) not useful (such as perpetual motion machines); or 2) offensive to public morality.
To be patentable, your invention must also be:
• Adequately described or enabled (for one of ordinary skill in the art to make and use the invention), and
• Claimed by the inventor in clear and definite terms
How do I know if my invention is patentable?
First, review the list of what can and cannot be patented and determine if your invention falls into one of those categories.
Next, a search of all previous public disclosures (prior art) including, but not limited to, previously patented inventions in the U.S. should be conducted to determine if your invention has been publicly disclosed and thus is not patentable. A search of foreign patents and printed publications should also be conducted. After an application is filed, the USPTO will conduct a search as part of the official examination process.
Who can apply for a patent?
A patent may be applied for only in the name(s) of the actual inventor(s).
Practice Tip #1: While performing a search of the prior art before filing an application is not required, it is wise to do so.
Practice Tip #2: You should not assume that your invention has not been patented even if you find no evidence of it being publicly disclosed. The examination at the USPTO may uncover U.S. and foreign patents as well as non-patent literature.
Practice Tip #3: Conducting a thorough patent search is difficult, particularly for the novice. Patent searching is a learned skill. A registered patent attorney is often a useful resource for performance of a patentability search.
Evansville, Indiana - In the matter of Berry Plastics Corp. v. Intertape Polymer Corp., Indiana patent attorneys for Berry Plastics Corporation ("Berry") invoked the crime-fraud exception to the attorney-client privilege, asking the court to compel Intertape Polymer Corporation ("Intertape") to produce documents and testimony it had withheld as privileged. Magistrate Judge William G. Hussmann, Jr. of the Southern District of Indiana denied the request.
This Indiana patent lawsuit was filed in January 2010 and seeks a declaratory judgment. Plaintiff Berry of Evansville, Indiana requested a judgment that Patent No. 7,476,416, titled Process for Preparing Adhesive Using Planetary Extruder, was invalid and unenforceable due to inequitable conduct before the U.S. Patent and Trademark Office ("USPTO") by Intertape, a company located in Bradenton, Florida.
In this current order, Magistrate Judge Hussmann addresses Berry's request to compel Intertape to produce documents and testimony that had been withheld as subject to attorney-client privilege. Indiana patent lawyers for Berry argued that this was proper because Intertape had engaged in inequitable conduct or defrauded the USPTO.
The Magistrate first emphasized that this ruling pertained only to discovery, as the question of whether Intertape had perpetrated a fraud upon the USPTO was one of the ultimate issues in the litigation. As such, that question of fact would be decided at trial by Chief Judge Richard L. Young.
The general rule in discovery is that a party to litigation is entitled to discover from his adversary "any nonprivileged matter that is relevant to any party's claim or defense." An exception to the attorney-client privilege is made when the communication between the attorney and the client is made in furtherance of a crime or fraud. To successfully invoke this exception, Berry must offer evidence demonstrating that:
1) Intertape made a false representation as to a material fact;
2) Intertape made its false representation with intent to deceive;
3) the USPTO justifiably relied upon Intertape's false representation; and
4) the USPTO suffered an injury as a consequence of its reliance on Intertape's false representation.
In an attempt to prove that the elements of the crime-fraud exception applied, Berry offered "numerous allegations and ... extensive evidence suggesting Intertape engaged in inequitable conduct or defrauded" the USPTO. Intertape responded to each allegation with "numerous defenses and extensive evidence suggesting its dealings with the USPTO were lawful and forthright."
The Magistrate held for Intertape. Citing Federal Circuit precedent, which governs the application of the crime-fraud exception to privilege in patent cases, the court called the piercing of the attorney-client privilege an "extreme remedy." The rule in such cases is that, if the court were to find Intertape's explanation satisfactory, it must leave the privilege intact. After an analysis of the defenses proffered by Intertape, the court found that Intertape's explanation for each of the allegations of fraud sufficient to avoid a piercing of the privilege.
Practice Tip: Magistrate judges are adjuncts to Article III district judges. They often dispose of pretrial matters such as motions, evidentiary hearings and pretrial conferences. However, their authority, and thus their role, in federal litigation is constrained by constitutional and statutory limits. Because the factual issue of whether Intertape committed fraud against the USPTO was one of the ultimate issues in the litigation, Magistrate Hussman expressly limited his ruling in this opinion to the discovery dispute before him. At trial, Chief Judge Young, in his role as the ultimate finder of fact, may determine that Intertape did, indeed, commit fraud.
Atlanta, Georgia -- Verint Systems Inc. ("VSI") of Melville, New York and its wholly owned subsidiary Verint Americas Inc. ("VAI") of Alpharetta, Georgia (collectively, "Verint") have sued Interactive Intelligence of Indianapolis, Indiana in the Northern District of Georgia for infringement of twenty separate patents; these patents have been registered with the U.S. Patent Office.
Verint is engaged in the business of inventing, developing, manufacturing, selling, installing, and/or distributing computer software and hardware products and systems. The products and systems are directed to, inter alia, the analysis, recording, monitoring, transmission, and/or security of electronic communications, such as telephonic, facsimile, and e-mail communications to and from contact centers and call centers which handle incoming and/or outgoing contacts with actual and prospective customers and clients. Verint's technology can provide an end user with the ability to capture, analyze and act on large volumes of complex information sources, such as voice, video, and unstructured text, which can enhance the ability of organizations of all sizes to make better decisions based on such information. Verint's main location for research and development relating to recording technology is located at VAI's facility in Georgia.
Verint's products and systems are used by more than 10,000 organizations in over 150 countries, including over 80 percent of the Fortune 100. For example, Verint's workforce-optimization and voice-of-the-customer solutions are designed to help organizations enhance customer-service operations in contact centers, branches, and back-office environments. This can increase customer satisfaction, reduce operating costs, uncover revenue opportunities and improve profitability. Verint uses its core competencies to develop highly scalable solutions with advanced, integrated analytics for both unstructured and structured information. Verint asserts that it has expended substantial resources inventing and developing this technology. Verint has licensed one or more of its patents to others in the industry through its Open Innovation Network ("OIN") licensing program.
Defendant Interactive, a competitor of Verint, is in a similar business. It manufactures, uses, sells, offers to sell, installs, distributes, exports, and/or imports computer software and hardware products and systems directed to and for use in connection with methods involving the analysis, recording, monitoring, transmission and security of electronic communications, such as telephonic communications to and from contact centers and call centers.
Verint contends that it is the sole owner of all rights to the patents at issue in this suit: U.S. Patent No. 5,790,798 ("the '798 patent"); U.S. Patent No. 7,203,285 ("the '285 patent"); U.S. Patent No. 7,376,735 ("the '735 patent"); U.S. Patent No. 7,574,000 ("the '000 patent"); U.S. Patent No. 7,774,854 ("the '854 patent"); U.S. Patent No. 7,852,994 ("the '994 patent"); U.S. Patent No. 7,903,568 ("the '568 patent"); U.S. Patent No. 8,204,056 ("the '056 patent"); U.S. Patent No. 8,285,833 ("the '833 patent"); U.S. Patent No. RE41,534 ("the '534 patent"); U.S. Patent No. RE43,324 ("the '324 patent"); U.S. Patent No. 8,401,155 ("the '155 patent"); U.S. Patent No. 8,359,434 ("the '434 patent"); U.S. Patent No. 8,345,828 ("the '828 patent"); U.S. Patent No. 8,275,944 ("the '944 patent"); U.S. Patent No. 8,204,053 ("the '053 patent"); U.S. Patent No. RE43,386 ("the '386 patent"); U.S. Patent No. 8,130,926 ("the '926 patent"); U.S. Patent No. 6,404,857 ("the '857 patent") and U.S. Patent No. 6,510,220 ("the '220 patent") (collectively, "the Patents-in-Suit").
Verint believes that Interactive is, in various ways, infringing upon the Patents-In-Suit. In a letter to Interactive dated September 13, 2010, VSI invited Defendant to participate in its OIN. The OIN is a licensing program under which VSI offers to grant a worldwide license to its portfolio of patents directed, in part, to the analysis, recording, monitoring, transmission, and/or security of electronic communications. In its September 2010 letter, VSI provided Interactive with claim charts showing how Interactive's activities fell within the claim scope of various patents within the OIN. Over the course of several months, several more letters were sent by VSI to Interactive, inviting it to participate in the OIN. No agreement was reached. The current lawsuit was subsequently filed by Verint.
Defendant Interactive is accused of infringing the Patents-in-Suit in violation of 35 U.S.C. § 271, including as follows:
(a) by making, using, offering to sell, and/or selling in the United States or importing into the United States computer software and/or hardware and/or systems, and/or by engaging in or practicing in the United States methods or processes covered by the Patents-in-Suit, including such methods or processes which utilize one or more of the Accused Products [those products of Interactive which are claimed to infringe on Verint's patents]; and/or
(b) by offering to sell or selling within the United States or importing into the United States a component of a product or system within one or more of the patents of the Patents-in-Suit, or a material or apparatus for use in practicing a method or process within one or more of the patents of the Patents-in-Suit, constituting a material part of one or more of the patents of the Patents-In-Suit, knowing the same to be especially made or especially adapted for use in an infringement of one or more of the patents of the Patents-in-Suit, and not a staple article or commodity of commerce suitable for substantial non-infringing use; and/or
(c) by supplying or causing to be supplied in or from the United States all or a substantial portion of components to form a product or system within one or more of the patents in the Patents-in-Suit, including by supplying or causing to be supplied in or from the United States the Accused Products, in such a manner as to actively induce the combination of such components outside of the United States in a manner that would infringe one or more of the patents of the Patents-in-Suit if such combination occurred within the United States; and/or
(d) by supplying or causing to be supplied in or from the United States a component of a product or system within one or more of the patents of the Patents-in-Suit that is especially made or especially adapted for use according to one or more of the patents of the Patents-in-Suit and is not a staple article or commodity of commerce suitable for substantial non-infringing use, knowing that such component is so made or adapted and intending that such component will be combined outside of the United States in a manner that would infringe one or more of the patents of the Patents-in-Suit if such combination occurred within the United States, including by supplying or causing to be supplied in or from the United States one or more of the Accused Products; and/or
(e) actively inducing one or more of the activities identified in subparagraphs (a) through (d).
Interactive is accused of infringing, contributing to the infringement of, and actively inducing infringement of the Patents-in-Suit. The complaint lists twenty counts of patent infringement:
- Count I: Infringement of the '798 patent
- Count II: Infringement of the '285 patent
- Count III: Infringement of the '735 patent
- Count IV: Infringement of the '000 patent
- Count V: Infringement of the '854 patent)
- Count VI: Infringement of the '994 patent
- Count VII: Infringement of the '568 patent
- Count VIII: Infringement of the '056 patent
- Count IX: Infringement of the '833 patent
- Count X: Infringement of the '534 patent
- Count XI: Infringement of the '324 patent
- Count XII: Infringement of the '155 patent
- Count XIII: Infringement of the '434 patent
- Count XIV: Infringement of the '828 patent
- Count XV: Infringement of the '944 patent
- Count XVI: Infringement of the '053 patent
- Count XVII: Infringement of the '386 patent
- Count XVIII: Infringement of the '926 patent
- Count XIX: Infringement of the '857 patent
- Count XX: Infringement of the '220 patent
In the complaint, patent attorneys for Verint assert that Interactive had actual knowledge and/or notice from a time prior to the filing of the present complaint of at least the following: the '798 patent; the '285 patent; the '735 patent; the '000 patent; the '854 patent; the '994 patent and the '534 patent. It is also alleged that Interactive's acts of infringement have been carried out deliberately and willfully, without the consent of Verint, at least with respect to the '798 patent; '285 patent; the '735 patent; the '000 patent; the '854 patent; the '994 patent and the '534 patent, entitling Verint to treble damages under 35 U.S.C. § 284. Verint further contends that this is an exceptional case entitling Verint to an award of attorneys' fees under 35 U.S.C. § 285.
Plaintiff Verint asks for a judgment that Defendant Interactive has been and is infringing, is contributing to the infringement of, and is actively inducing infringement of the Patents-in-Suit; preliminary and permanent injunctive relief against such infringement under 35 U.S.C. § 283; damages, including treble damages, by reasons of Defendant's acts of purportedly deliberate and willful infringement; attorneys' fees; and costs, including expert witness fees.
Practice Tip: Verint is no stranger to the value of intellectual property. It utilizes more than 1,000 employees and contractors in research and development throughout the world, and has obtained or filed more than 570 patents and applications worldwide. In its last fiscal last year, Verint obtained issuance or allowance of 60 patents and applications in the United States.
Verint is also no stranger to intellectual property lawsuits. In 2008, a Georgia jury found that NICE Systems Ltd. had infringed Verint's U.S. Patent No. 6,404,857 and awarded Verint $3.3 million in damages. A week later, in a separate lawsuit, Verint was found not to have infringed NICE's U.S. Patent No. 6,871,229. There have been at least three other patent infringement lawsuits between Verint and NICE. There were rumors in January that NICE was negotiating to acquire Verint Systems, Inc.
Supreme Court Of The United States Reversed The Federal Circuit On Method Claim For Treating Autoimmune Diseases Are Not Eligible For Patent Protection
Washington, D.C. - The United States Supreme Court has unanimously reversed a patent decision by the Court of Appeals for the Federal Circuit and has held that patent claims that are a "law of nature" are not patent eligible under 35 U.S.C. § 101. The decision built upon the Court's 2010 decision in Bilski v. Kappos.
Patent lawyers for Prometheus Laboratories, Inc. of
The patents at issue involve claims over an observed correlation between certain blood tests and patient health, specifically the correlation between the level of certain drug metabolites in the patient's blood and the patient's symptoms of gastrointestinal disease. The Court of Appeals for the Federal Circuit had twice ruled in Prometheus's favor. Oral arguments were held December 7, 2011 at the United States Supreme Court. The Court decision essentially held that Prometheus's "invention" was not patentable because it was effectively a law of nature. In other words, the relationship between the dosages and the effect on patient health was a natural phenomenon and therefore, unpatentable.
We blogged a preview of this case in October. This ruling is being criticized by the patent bar as making the law less clear. In particular, Robert S. Sachs of Fenwick & West LLP is examining the decision in a series of blogs on Patently-O in which he examines "just some of the logical and legal errors in the Court's decision." Sachs commentary also suggests that numerous patents should now be found invalid.Practice Tip: The Court's decision has immediately changed protocol at the patent examination office. The US Patent Office has issued new guidelines to patent examiners which are available here.
The plaintiff claims that the defendants sell dynamic pricing software products aimed at pricing tickets for events by a variety of names "Dynamic Pricing Dashboard," "the Qcue Product," and "software-based dynamic pricing solution" that infringe the patents held by Digonex. The technology is apparently marketed to sports teams and event promoters. The complaint alleges that Qcue has sold infringing products to Major League Baseball, Major League Soccer, National Basketball Association, National Hockey League and NASCAR. The complaint makes two claims of patent infringement and seeks a declaration of infringement, an injunction, damages, attorney fees and costs. The complaint also alleges that Qcue has the specific intent to induce others to infringe Digonex's patents.
Practice Tip: The complaint alleges that Qcue has referenced the two Digonex patents in a Qcue patent application pending before the US Patent Office. This, in part, is Digonex's "evidence" of willful infringement. Also, Patent Office's records reveal that in prosecuting the 8,095,424 patent it submitted an Information Disclsosure Statement on September 30, 2011, after the claims had been allowed. However, the Patent Office refused to consider the IDS becuase it did not comply with Patent Office regulations. Therefore, there may be some question regarding the validity of this patent.
Federal Circuit Court of Appeals Affirms that It May Hear Legal Malpractice Claims Involving Patent Issue
Washington, DC - A recent decision in the Federal Circuit Court of Appeals in a legal malpractice claim involving a patent issue may have an impact on a recently filed Indiana case alleging patent attorneys committed legal malpractice, which was filed by Purdue Research Foundation late last month.
In Byrne v. Wood, Herron & Evans LLP, the Federal Circuit Court of Appeals vacated a summary judgment in favor of the law firm Wood, Herron & Evans, and remanded to the lower court for further proceedings. The plaintiff sued the law firm for legal malpractice for failing to secure a patent that was broad enough to secure his invention of a grass and weed trimmer. The plaintiff claimed that due to the law firm's failure, he later lost a patent infringement lawsuit against Black & Decker. The court below granted summary judgment for the law firm, based in part on its decision that Mr. Byre was not an expert witness.
The appellate court also briefly took on the question of whether the federal courts have jurisdiction to hear legal malpractice claims, typically arising out of state law, when a patent issue is intertwined. The Court, citing Davis v. Brouse McDowell, L.P.A., 596 F.3d 1355 (Fed. Cir. 2010), confirmed that it did have jurisdiction over this case. However, the court acknowledged that other courts had disagreed.
The opinion is designated "non-precedential." This was an appeal from the Eastern District of Kentucky.Practice Tip: The basis of the legal malpractice claims in the Purdue case are substantially different that here, however, this case confirms that in most situations involving a patent issue is appropriate for the federal courts to hear legal malpractice cases.
Indiana District Court's Verdict for Alcon Laboratories in Patent Infringement Suit Over Eye Medication Now Pending on Appeal
Indianapolis, IN - A patent infringement judgment from the Southern District of Indiana will be reviewed by the Federal Circuit Court of Appeals. In May, Chief Judge Richard L. Young of the Southern District of Indiana issued a verdict and judgment in favor of plaintiffs Alcon Research Ltd., Alcon Laboratories, Inc., both of Fort Worth, Texas and Hakko Kirin Co., Ltd. (f/k/a Kyowa Hakko Kogyo Co., Ltd.) of Tokyo, Japan, after a bench trial on the plaintiff's patent infringement claims against Apotex, Inc., of Ontario, Canada and Apotex Corp. Weston, Florida. Alcon filed a complaint alleging Apotex infringed patent no.5,641,805, TOPICAL OPHTHALMIC FORMULATIONS FOR TREATING ALLERGIC EYE DISEASES, which has been issued by the US Patent Office.
Chief Judge Young presided over a bench trial April 26, 2010 to May 7, 2010, and final arguments were presented to the court on August 3, 2010. The Court found that plaintiffs had "proven, by a preponderance of the evidence, that the Defendants' generic equivalent of Plaintiffs' patented allergy topical ocular medication, Patanol®;, infringed claims 1-8 of the '805 patent[,]" and that the defendant failed to show, by preponderance of evidence, that the patent claims were invalid. The court also found that the defendants failed to prove, by preponderance of evidence, that the '805 patent is unenforceable due to inequitable conduct.
Apotex has appealed the case to the Federal Circuit Court of Appeals (docket number 2011-1455). Apotex's brief was filed on October 3, 2011, and Alcon's brief is due on December 23, 2011.
Practice Tip: One of the defenses raised by Apotex was to claim the patent was unenforceable due to inequitable conduct. Apotex claimed that one of the inventors of the '805 failed to disclose results of certain tests and other data in the patent application. Apotex claimed the inventor as well as the attorney who filed the patent application violated their duty of candor to the PTO, which is imposes pursuant federal regulations 37 C.F.R. § 1.56(c). Alcon, however, presented evidence that the tests in question were believed to be inconclusive and that the inventor simply forgot about another test. Under the totality of circumstances, the court found that a finding of deceptive intent was not warranted. The court, therefore, declined to find that the patent should not be enforceable under the theory of inequitable conduct.In addition, the court held that Apotex could not raise an additional theory of invalidity - invalidity for lack of a written description - until after the trial. The court found that the late disclosure had prejudiced the plaintiff and therefore refused to consider the new theory.
Purdue Research Foundation Sues Morrison & Foerster, LLP over a Trade Secret, Case Removed to Federal Court
Lafayette, IN - Attorneys for the Purdue Research Foundation ("PRF") of West Lafayette, Indiana have file a suit against the law firm of Morrison & Foerster, LLP alleging that Morrison & Foerster filed a patent application without PRF's authorization, specifically for patent PCT2009/060273 and misappropriated trade secrets in the course of filing this patent application.
PRF filed the original complaint in Tippecanoe County Circuit Court on October 7, seeking a permanent injunction to prevent Morrison from continuing the patent application, on which Morrison listed itself and PRF as the co-applicants. The original complaint alleges that Morrison continued to breach its fiduciary duties to PRF through continuing to prosecute the patent application. Morrison filed to have the case removed to federal court, arguing that the case involved the federal questions of the inventorship of the claimed invention under the '273 patent.
Morrison's removal notice notes that PRF is currently involved in related lititgation against CoMentis Incorporated, who is Morrison's client. In that lawsuit, PRF alleges that CoMentis improperly disclosed trade secrets, which are covered by PRF's patents, when it filed the '273 patent application. Morrison states that this new case "is really an attempt by PRF to enjoin or otherwise interfere with an inventor's (CoMentis's) attempt to prosecute a patent application."Practice Tip: In this case, PRF has alleged that Morrison owed it a fiduciary duty since Morrison filed the patent application and listed PRF as a co-applicant. Morrison disputes that it owed a fiduciary duty to PRF and states that any existence of a fiduciary duty would be governed by the Code of Federal Register, thus creating a federal question. In addition to this federal question, Morrison states PRF's complaint is really an "inventorship" dispute, which is also a federal question.
According to the Indianapolis Business Journal, Lilly continues to maintain the patent is invalid. The IBJ quoted a Lilly statement as stating "Human Genome Sciences seek to foreclose a whole area of research in a way that is not only harmful to the industry, but would ultimately and unjustifiably hinder the future development of new medicines." Practice Tip: The Court's decision was based upon the European Patent Convention and
According to the Indianapolis Business Journal, Lilly continues to maintain the patent is invalid. The IBJ quoted a Lilly statement as stating "Human Genome Sciences seek to foreclose a whole area of research in a way that is not only harmful to the industry, but would ultimately and unjustifiably hinder the future development of new medicines."
Practice Tip: The Court's decision was based upon the European Patent Convention and
Preview of U.S. Supreme Court Patent Infringement Case Mayo Collaborative Services v. Prometheus Labs
Washington, D.C. - The United States Supreme Court will hear an important patent infringement case this term that will determine the scope of patent rights in certain medical methods. Patent lawyers for Prometheus Laboratories, Inc. of San Diego, California filed a patent infringement suit against Mayo Collaborative Services, doing business as Mayo Medical Laboratories of Rochester, Minnesota, alleging that Mayo infringed patent no. 6,355,623, Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage and patent no. 6,680,302, Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders which have been issued by the US Patent Office.
The patents at issue involve claims over an observed correlation between certain blood tests and patient health, specifically the correlation between the level of certain drug metabolites in the patient's blood and the patient's symptoms of gastrointestinal disease. As characterized by Mayo in its brief to the Supreme Court, the inventors did not "invent" these correlations; rather, they simply observed the correlations in a patient population. Based on the patents, Prometheus brought a blood test product called Pro-Predict to the market. The level of metabolite in the patient's blood can give the treating physician information relevant to adjusting the patient's dose of certain medications. Mayo improved upon Prometheus's blood test product and later released its own competing product. Patent attorneys for Prometheus then initiated this lawsuit, alleging that Mayo had infringed its patents. Mayo has attempted to defend the suit by arguing that Prometheus's patent claims were not patent-eligible under 35 U.S.C. § 101. The Court of Appeals for the Federal Circuit has twice ruled in Prometheus's favor.
The oral argument is scheduled for December 7, 2011 at the United States Supreme Court. The briefs can be found on the American Bar Association's preview page for the case. A number of amicus curiae briefs have been filed as well. Notably, the American Medical Association filed an amicus brief in support of Mayo.Bilski v. Kappos, which examined § 101 and held the machine-or-transformation test is not the sole test for determining patent eligibility, but is rather "a useful and important clue, an investigative tool, for determining whether some claimed inventions are processes under § 101." The decision in this case may clarify the Bilski holding.
Washington, DC - On Monday, October 3, 2011, the U.S. Supreme Court opened its session and refused to review several appellate decisions in patent, trademark and copyright cases. These included the following cases:
Lockwood v. Sheppard, Mullin, Richter, & Hampton, LLP., U.S., No. 10-1339.
The Federal Circuit summarily affirmed a district court dismissal of a patent owner's malicious prosecution suite against the patent attorney that requested the USPTO to reexamine his patents. The patent owner had alleged, among other things, that the law firm filed a sham reexamination request with misrepresentations of the prior art. The district court held that the state law claims were essentially allegations of fraud and bad faith before the USPTO, preempted by federal law under Buckman Co. v. Plaintiffs' Legal Committee, 531 U.S. 341 (2001). The district court also found the claims over the 2003 reexamination request barred by the two-year statute of limitations.
ASCAP v. United States, U.S., No. 10-1337.
In this case, the Second Circuit affirmed summary judgment that downloading a musical work implicates the reproduction right, but not the public performance right, 627 F.3d 64 (2010). The decision arose in an action over music royalties brought by copyright attorneys for Yahoo and RealNetworks in New York district court. The Second Circuit held that the performance of a work requires that the work be "contemporaneously perceptible," which may be the case for streamed music but is not the case for downloaded music.
While the Supreme Court decides to review relatively few intellectual property cases, one case they are considering in December 2011 involves the patentability of pharmaceutical processes. In Mayo v. Prometheus it has asked the parties to answer the following question:
"Whether 35 U.S.C. § 101 is satisfied by a patent claim that covers observed correlations between blood test results and patient health, so that the claim effectively preempts all uses of the naturally occurring correlations, simply because well-known methods used to administer prescription drugs and test blood may involve "transformations" of body chemistry."Oral argument is set for December 7, 2011
Southern District of Indiana Issues Markman Ruling in Cook Inc. v. Endologix Patent Infringement Case Over Aortic Stent
Indianapolis, IN - The Southern District of Indiana has issued a claim construction order in a patent infringement lawsuit. Cook Incorporated, of Bloomington, Indiana, had filed a patent infringement lawsuit in the Southern District of Indiana against Endologix, Inc., of
The patents at issue are medical devices that are used to treat abdominal aortic aneurysms, which are caused by the weakening of the aorta. The patented technologies are stents that strengthen the walls of the aorta and delivery systems. Cook alleges that Endologix's Powerlink product infringes its patents. On April 15, 2011, the court held a Markman hearing to determine whether the patents cover the alleged infringer's product. The parties disputed whether certain features of Endologix product were covered by Cook's patents and the meaning of specific terms in the patent's claims. Judge Pratt's order set out the meaning of over thirty the disputed claim terms.
According to Yahoo Finance, Endologix has interpreted the rulings to be favorable.
Practice Tip: As the court described in its opinion, "[i]n order to win a patent infringement suit, a plaintiff must establish that the patent claim "covers the alleged infringer's product or process." Markman, 517
Federal Circuit Applies Analogous Art Test to Exclude Prior Art References from Obviousness Analysis
Washington, DC - In a decision that may impact both patent prosecutors and litigators, the United States Court of Appeals for the Federal Circuit applied the analogous-art test to exclude certain prior art references from the consideration of whether a claimed invention was obvious in light of the prior art.In this case, patent applicant Arnold Klein appealed the rejection of certain claims in U.S. Patent Application No. 10/200,747 as obvious under 35 U.S.C. § 103. The relatively simple technology at issue is "a mixing device for use in preparation of sugar-water nectar for certain bird and butterfly feeders," with sugar and water compartments separated by a removable divider. The placement of the divider can vary, depending on the species of bird to be fed. The device maintains a proper nectar ratio so long as water and sugar are at the same "line of sight" level.Citing prior art patents, the examiner at the USPTO made five rejections, each based on the notion that Mr. Klein's invention would be obvious to one of ordinary skill in the art, and these rejections were each affirmed by the Board of Patent Appeals and Interferences ("the Board").
Noting that a reference qualifies as prior art for an obviousness determination under § 103 only when it is "analogous" to the claimed invention, the Federal Circuit initially focused on the particular problem being solved by Mr. Klein and narrowly stated it as: "making a nectar feeder with a movable divider to prepare different ratios of sugar and water for different animals." The court found that the three cited prior art references (respectively disclosing a type of drawer, a particular tray, and an "apparatus for keeping accounts") which feature solid item separators are not pertinent to this problem "since none of these three references shows a partitioned container that is adapted to receive water or contain it long enough to be able to prepare different ratios in the different compartments."
As for the two remaining prior art references (disclosing a type of "blood plasma bottle" and a certain fluid container), they are directed at dividing liquids which are mixed later; the Federal Circuit concluded that neither of these references are pertinent to Mr. Klein's invention "because they do not address multiple ratios or have a 'movable divider'." Because none of the cited references were completely analogous to the stated problem, no grounds remained to support the obviousness rejections, and the Board's decision was reversed.
Practice Tip: Curiously, this opinion does not address the KSR Int'l Co. v. Teleflex, Inc., 550 U.S. 398 (2007), decision by the United States Supreme Court, which allows for consideration of subjective "common sense" when determining whether a person of ordinary skill in the art would find motivation to combine elements known in the prior art. This failure to consider KSR may limit the impact of the Klein decision.
Under this program, if an eligible utility patent applicant electronically files a request prior to the first Office action on the merits, he or she must be granted an interview with the patent examiner assigned to the case. Traditionally, the grant of such a preliminary interview was with the discretion of the examiner.
To be eligible, the subject patent application must not have more than three independent claims and twenty or fewer total claims that are directed to a single invention.
After a proper request has been filed, the examiner will conduct a prior art search and provide the applicant with a Pre-Interview Communication which will include cites to prior art references and an identification of potential rejections and/or objections (if at least one claim is not allowable).
The electronic requests to participate may be filed as of May 16, 2011, and the program will run for one year from that date. No additional fees are required to participate.The USPTO previously conducted this sort of program as an experiment in certain technical areas under the name Enhanced First Action Interview Pilot Program. The present expansion of the program is based upon comments from the public as well as USPTO professionals.